Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the first quarter ended March 31, 2011. (Photo:...
Cardium Therapeutics (NYSE AMEX: CXM) today presented highlights of financial results for its fourth quarter and fiscal year ended December 31, 2010, ...
Cardium Therapeutics (NYSE Amex: CXM) today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study. The...
Cardium Therapeutics (NYSE Amex: CXM) reported that its exchange listing compliance plan submitted on December 2, 2010 has been accepted by the NYSE...
Cardium Therapeutics (NYSE Amex: CXM) today announced plans to introduce non-prescription Cerex™ (Panax quinquefolius) easy use 200 mg capsules, a...
Cardium Therapeutics (NYSE Amex: CXM) today announced today that it is scheduled to present at the OneMedForum Finance Conference for Emerging...
Cardium Therapeutics (NYSE Amex: CXM) today reported that data from the Company's Matrix Phase 2b clinical study has been accepted for publication in ...
Cardium Therapeutics (NYSE Amex: CXM) reported on a communication from the staff of the company's current listing exchange indicating that it...
Cardium Therapeutics (NYSE Amex: CXM) today announced a co-development and strategic licensing agreement with BioZone Laboratories, Inc. ("BioZone")...
Cardium Therapeutics (NYSE Amex: CXM) reported on the presentation of results from the Company's sponsored preclinical research at the American Heart ...
Cardium Therapeutics (NYSE Amex: CXM) today reported highlights and financial results for its third quarter ended September 30, 2010. Highlights of...
Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at...
Cardium Therapeutics (NYSE AMEX: CXM) today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's...
Cardium Therapeutics (NYSE Amex: CXM) today reported on new preclinical research findings that Excellagen, a topically applied formulated collagen...
Cardium Therapeutics (NYSE Amex: CXM) announced that it has gained exclusive access to commercial development rights for certain novel...
Cardium Therapeutics (NYSE Amex: CXM) today announced the addition of a new weight management product, Appexium™, to Cardium's MedPodium™ product...
Cardium Therapeutics (NYSE Amex: CXM) today reported that the Company has received a letter from the NYSE Amex LLC informing Cardium that it has now...
Cardium Therapeutics (NYSE Amex: CXM) today reported on its exchange listing compliance with NYSE Amex LLC (formerly the American Stock Exchange)....
Cardium Therapeutics (NYSE Amex: CXM) today announced Dominique Dawes, an Olympic champion, as the official web-based spokesperson for the Company's...
Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into a Master Services Agreement with bioRASI, an international contract...
Cardium Therapeutics (NYSE Amex: CXM) today announced that its wholly-owned subsidiary, Tissue Repair Company, has entered into a multi-year supply...
Cardium Therapeutics (NYSE Amex: CXM) today reported highlights and financial results for its first quarter ended March 31, 2010. Highlights of the...
Cardium Therapeutics (NYSE Amex: CXM) has been invited to present at the 2010 MDB Capital Group's Bright Lights Conference. The conference will be...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.